$1.26 Billion is the total value of Sarissa Capital Management LP's 14 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Buy | Alkermes PLC | $291,052,000 | +96.0% | 11,870,000 | +49.3% | 23.14% | +62.6% |
| BIIB | BIOGEN INC | $222,651,000 | +23.8% | 643,000 | 0.0% | 17.70% | +2.7% | |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $210,939,000 | +15.1% | 16,390,000 | 0.0% | 16.77% | -4.5% | |
| GILD | Gilead Sciences Inc | $185,742,000 | +6.5% | 2,697,400 | 0.0% | 14.77% | -11.6% | |
| ALXN | Alexion Pharmaceuticals Inc | $119,492,000 | +20.1% | 650,440 | 0.0% | 9.50% | -0.3% | |
| INVA | INNOVIVA INC | $86,011,000 | +12.2% | 6,414,000 | 0.0% | 6.84% | -6.9% | |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $67,366,000 | -13.3% | 4,261,000 | -44.2% | 5.36% | -28.1% |
| MRSN | MERSANA THERAPEUTICS INC | $54,396,000 | -16.1% | 4,005,600 | 0.0% | 4.32% | -30.4% | |
| VOR | VOR BIOPHARMA INC | $13,186,000 | -56.7% | 707,010 | 0.0% | 1.05% | -64.1% | |
| SRSAW | SARISSA CAPITAL ACQUISITN COw exp 10/23/202 | $4,999,000 | 0.0% | 3,333,333 | 0.0% | 0.40% | -17.1% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,506,000 | -47.9% | 1,851,851 | 0.0% | 0.12% | -56.7% | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $177,000 | +7.9% | 1,000 | 0.0% | 0.01% | -12.5% | |
| MRTX | MIRATI THERAPEUTICS INC | $161,000 | -5.8% | 1,000 | 0.0% | 0.01% | -18.8% | |
| ICPT | INTERCEPT PHARMACEUTICALS INC | $18,000 | -14.3% | 950 | 0.0% | 0.00% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.